Inovio Pharmaceuticals Inc [INO] stock is trading at $10.18, up 12.74%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The INO shares have gain 6.60% over the last week, with a monthly amount glided 92.44%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights. In a post published today on Yahoo Finance, Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP).
From an analyst’s perspective:
Inovio Pharmaceuticals Inc [NASDAQ: INO] stock has seen the most recent analyst activity on January 25, 2024, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $4 for it. Previously, Maxim Group downgraded its rating to Hold on November 09, 2022. On November 01, 2022, downgrade downgraded it’s rating to Underperform but maintained its price target of $2 on the stock. Oppenheimer downgraded its rating to a Perform. BofA Securities upgraded its rating to Neutral for this stock on January 21, 2022, and upped its price target to $10.
Inovio Pharmaceuticals Inc [INO] stock has fluctuated between $3.89 and $14.88 over the past year. Inovio Pharmaceuticals Inc [NASDAQ: INO] shares were valued at $10.18 at the most recent close of the market.
Analyzing the INO fundamentals
Inovio Pharmaceuticals Inc [NASDAQ:INO] reported sales of 0.83M for the trailing twelve months, which represents a drop of -17.66%. Gross Profit Margin for this corporation currently stands at -38.46% with Operating Profit Margin at -201.98%, Pretax Profit Margin comes in at -192.71%, and Net Profit Margin reading is 3310.9%. To continue investigating profitability, this company’s Return on Assets is posted at 14.64, Equity is 15.51 and Total Capital is -1.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.19 points at the first support level, and at 8.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.96, and for the 2nd resistance point, it is at 11.73.
Inovio Pharmaceuticals Inc [INO] reported earnings per share of -$1.12 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.27/share, meaning a difference of $0.15 and a surprise factor of 11.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.56 per share as compared to estimates of -$1.52 per share, a difference of -$0.04 representing a surprise of -2.60%.
Ratios To Look Out For
For context, Inovio Pharmaceuticals Inc’s Current Ratio is 3.60. As well, the Quick Ratio is 3.60, while the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 286.63, the price to book ratio is 1.98.
Transactions by insiders
Recent insider trading involved Zoth Lota S., Director, that happened on Jun 05 ’23 when 5700.0 shares were sold. Director, Weiner David B. completed a deal on Mar 13 ’23 to sell 5833.0 shares.
